Lakefront Biotherapeutics Completes Share Repurchase Program

On October 20, 2026, Lakefront Biotherapeutics NV announced the completion of its share repurchase program originally initiated on June 9, 2026. Between October 12, 2026, and October 16, 2026, the company repurchased a total of 107,804 ordinary shares through an independent financial intermediary. These transactions were executed across various markets including XAMS, CEUX, AQEU, and TQEX at an average price of €26.48 per share, representing a total investment of approximately €2.85 million during this final period. Following these transactions, the company holds a total of 1,985,157 of its own ordinary shares. Lakefront Biotherapeutics is a clinical-stage biotechnology company focused on immunology and inflammation, with its lead candidate being gamgertamig, a BCMAxCD3 T-cell engager for autoimmune diseases. The company confirmed that with these latest purchases, the previously announced buyback program is now fully concluded.